Ground News

institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Pharmaceutical-technology.com image

News from pharmaceutical-technology.com

See all of Pharmaceutical-technology.com’s headline news. Compare how the top news stories are covered by left-wing and right-wing news sources.

In total, 384 have been published by Pharmaceutical-technology.com which Ground News has aggregated in the past 3 months.

Ground News rates Pharmaceutical-technology.com’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Pharmaceutical-technology.com’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Pharmaceutical-technology.com

Where is Pharmaceutical-technology.com located?Pharmaceutical-technology.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Pharmaceutical-technology.com News

With FDA Nod in Lung Cancer, Dizal Now Aims to Best a J&J Drug and Succeed Where Takeda Fell Short

Johnson & Johnson · United States

With FDA Nod in Lung Cancer, Dizal Now Aims to Best a J&J Drug and Succeed Where Takeda Fell Short

71% Center coverage: 32 sources

Dizal Pharmaceutical’s Zegfrovy is now FDA approved for treating non-small cell lung cancer driven by a particular rare genetic signature. Johnson & Johnson drug Rybrevant already addresses this genetic signature as an earlier line of therapy, but Dizal executives contend their drug offers the potential for better safety and efficacy. The post With FDA Nod in Lung Cancer, Dizal Now Aims to Best a J&J Drug and Succeed Where Takeda Fell Short appe…See the Story

Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China

Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China

43% Left coverage: 14 sources

Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater ChinaBrii Biosciences retains ex-Greater China rights to address the global antimicrobial resistance threats and continues investment in other priority pipeline assets See the Story

Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak

Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak

50% Left coverage: 8 sources

Offer of US$3.01 in cash plus one contingent value right for potential additional aggregate payments of up to US$1.19 per shareUpfront and total potential...See the Story

Blindspots

Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak

The 3 key NHS changes set out in Labour’s 10 Year Plan explained

57% Center coverage: 7 sources

Labour set out its long-term plan for the NHS todayKeir Starmer · United Kingdom See the Story

Advancing Bone Health: European Commission Approves Biocon Biologics' Denosumab Biosimilars

67% Right coverage: 3 sources

/PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that the European...European Union See the Story

Lunit Partners With Microsoft To Develop AI Cancer Diagnostic Tools - Data Intelligence

According to GlobalData analysis, the use of AI across healthcare is rapidly advancing, with the market projected to reach a valuation of around $19bn by 2027. Image credit: MONOPOLY919 via Shutterstock. South Korean AI company Lunit is collaborating with Microsoft to help bring its AI-powered diagnostics for cancer detection into clinical practice. According to Lunit, the partnership aligns with its vision to create AI tools that fit smoothly i…Cancer · Seoul See the Story

Big pharma braces for revenue headwinds as patent expiries loom - Pharmaceutical Technology

More than half of the top 15 pharma companies are expected to face challenges in managing the patent cliff.Pharma · United States See the Story

AZ Claims EU Okay for Imfinzi in Bladder Cancer

100% Center coverage: 1 sources

AstraZeneca passes another milestone in its journey to rebuild Imfinzi's presence in bladder cancer, a key growth driver for the drugEuropean Union See the Story

Protecting Patients' Data Is Vital For NHS Single Health Record System - Data Intelligence

The recent Westminster Health Forum included UK health specialists who discussed the benefit, risk and complications of creating a single, patient data system. Image credit: Marbury / Shutterstock. Experts are emphasising that safeguarding patient data from corporations and cyberattacks is vital for the NHS to create a single health record database. The UK Government is pushing for a move towards a single, unified digital patient record within t…NHS · United Kingdom See the Story

Regeneron Gets Long-Awaited FDA Okay for Myeloma Drug

Coverage: 2 sources

Regeneron's bid to join the crowded US market for BCMA-targeted bispecific antibodies for multiple myeloma has finally been realisedFDA · United States See the Story

Ligand’s LNHC Concludes Merger with CHRO

Ligand Pharmaceuticals’ subsidiary LNHC has concluded its merger with CHRO Merger Sub to form a new entity, Pelthos Therapeutics.See the Story

Breaking News Topics Related to Pharmaceutical-technology.com